Drug Trial Radar · NCT07684742
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,200
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Jul 1, 2031
Study completion Jan 31, 2033
Sponsor
- Lead sponsor
- Gyeongsang National University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Genoss Co., Ltd.; CGBio Inc.; Osstem vascular; Dio
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, multicenter, randomized, phase IV clinical trial designed to evaluate the safety and efficacy of early aspirin discontinuation followed by potent P2Y12 inhibitor monotherapy after intravascular ultrasound (IVUS)-guided drug-eluting stent implantation in patients with acute coronary syndrome. A total of 2,200 patients who achieve complete revascularization after IVUS-guided percutaneous coronary intervention (PCI) and meet the predefined successful IVUS-guided PCI criteria will be randomized in a 1:1 ratio to either the early single antiplatelet therapy group (Early SAPT: ticagrelor or prasugrel monotherapy) or the standard dual antiplatelet therapy group (Standard DAPT: aspirin plus ticagrelor or prasugrel). Randomization will be performed within 96 hours after completion of PCI, and clinical follow-up will be conducted at 1 month, 3 months, 6 months, and 12 months after randomization. The primary endpoints are major adverse cardiovascular events, defined as a composite of all-cause death, myocardial infarction, ischemia-driven target vessel revascularization, and definite or probable stent thrombosis occurring up to 12 months after randomization, and clinically relevant bleeding, defined as Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding occurring up to 12 months after randomization. This study aims to determine whether early P2Y12 inhibitor monotherapy is non-inferior to standard dual antiplatelet therapy (DAPT) for ischemic events and is superior in reducing clinically relevant bleeding.
Conditions
- Acute Coronary Syndromes
- STEMI
- NSTEMI
- Unstable Angina
Interventions
Early P2Y12 Inhibitor MonotherapyDrug
Participants randomized within 96 hours after successful IVUS-guided PCI will discontinue aspirin immediately after randomization and receive potent P2Y12 inhibitor monotherapy with ticagrelor 90 mg twice daily or prasugrel 10 mg once daily. However, in patients aged ≥75 years, weighing \<60 kg, or considered at high bleeding risk, a reduced dose of ticagrelor (60 mg twice daily) or prasugrel (5 mg once daily) may be administered at the operator's discretion.
Standard Dual Antiplatelet TherapyDrug
Participants randomized within 96 hours after successful IVUS-guided PCI will receive aspirin 100 mg once daily plus a potent P2Y12 inhibitor, consisting of ticagrelor 90 mg twice daily or prasugrel 10 mg once daily, for 12 months. However, in patients aged ≥75 years, weighing \<60 kg, or considered at high bleeding risk, a reduced dose of ticagrelor (60 mg twice daily) or prasugrel (5 mg once daily) may be administered at the operator's discretion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Adverse Cardiovascular EventsTime frame: Up to 12 months after randomization
- Clinically Relevant BleedingTime frame: Up to 12 months after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gyeongsang National University Hospital
Jinju, Gyeongsangnam-do, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.